By using foundation models to analyze vast datasets, companies can create a synthetic 'standard of care' arm for single-arm Phase 1 trials. The AI matches patients based on deep clinical and genomic parameters, providing insights comparable to a much larger Phase 3 trial.

Beyond early discovery, LLMs deliver significant value in clinical trials. They accelerate timelines by automating months of post-trial documentation work. More strategically, they can improve trial success rates by analyzing genomic data to identify patient populations with a higher likelihood of responding to a treatment.

Contrary to the belief that AI needs massive datasets, Dr. Joseph Juraji's approach with NetraAI focuses on finding small, specific patient subpopulations within small trials. This allows the identification of a drug's 'superpower' without the need for big data, transforming trial economics.

Rather than aiming directly for high-stakes clinical trials, Effion Health's go-to-market strategy begins with post-market, real-world evidence studies. This approach allows them to demonstrate their technology's value in a real-world setting, building a strong case for adoption in earlier, more critical drug development phases.

By continuously measuring a drug's effect on the body (pharmacodynamics), the wearable device provides a real-time view of a patient's phenotype. This granular data can revolutionize clinical trial design, safety monitoring, and drug dosing, moving beyond static genomic data to understand real-world drug response.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

While most focus on AI for drug discovery, Recursion is building an AI stack for clinical development, where 70% of costs lie. By using real-world data to pinpoint patient locations and causal AI to predict responders, they are improving trial enrollment rates by 1.5x. This demonstrates a holistic, end-to-end AI strategy that addresses bottlenecks across the entire value chain, not just the initial stages.

Traditional clinical assessments, like the six-minute walk test, are easily skewed by external factors such as patient fatigue. Effion Health's digital biomarker system can isolate and measure the underlying pathological movement patterns, providing a more sensitive and precise measurement of disease progression regardless of temporary conditions.

Fibrogen uses its PET imaging agent in Phase 2 not to pre-select patients, but to correlate target expression with treatment response. This data will allow them to enrich their Phase 3 trial with patients most likely to respond, significantly increasing the probability of success.